Rhythm Pharmaceuticals Utdelningar och återköp
Utdelning kriterier kontrolleras 0/6
Rhythm Pharmaceuticals har inte registrerat sig för att betala utdelning.
Viktig information
n/a
Avkastning på utdelning
-4.2%
Återköpsavkastning
| Total avkastning till aktieägarna | -4.2% |
| Framtida utdelningsavkastning | 0% |
| Utdelningstillväxt | n/a |
| Nästa utbetalningsdag för utdelning | n/a |
| Ex utdelningsdag | n/a |
| Utdelning per aktie | n/a |
| Utdelningsandel | n/a |
Senaste utdelnings- och återköpsuppdateringar
Inga uppdateringar
Recent updates
RYTM: Hypothalamic Obesity Approval Will Drive Next Phase Of Upside
Analysts have nudged their blended price target for Rhythm Pharmaceuticals higher by $0.40 to $137.67, reflecting updated assumptions around revenue growth, profitability, discount rates, and future P/E multiples following recent research updates on Phase 3 trial outcomes and the commercial outlook for Imcivree and hypothalamic obesity. Analyst Commentary Recent research updates present a mixed but generally constructive picture, with several firms adjusting price targets following the EMANATE trial results and evolving expectations for Imcivree and hypothalamic obesity.RYTM: Hypothalamic Obesity Expansion Will Drive Next Upside Phase
Rhythm Pharmaceuticals' fair value estimate has moved higher to $137.27 from $135.53, as analysts factor in recent price target revisions that balance EMANATE trial setbacks with continued focus on Imcivree commercial execution and next generation MC4R agonists. Analyst Commentary Street research around Rhythm Pharmaceuticals has shifted meaningfully following the EMANATE readout, with price targets adjusted both higher and lower as analysts weigh clinical risk against the commercial rollout of Imcivree and the potential of next generation MC4R agonists.RYTM: Hypothalamic Obesity Approval And Launch Preparations Will Drive Next Upside Phase
The updated analyst model trims the blended price target for Rhythm Pharmaceuticals by about $4 to $135.53 as analysts factor in slightly lower revenue growth and margin assumptions, along with a higher projected future P/E multiple following recent EMANATE trial results and ongoing focus on Imcivree and hypothalamic obesity. Analyst Commentary Recent Street research around Rhythm Pharmaceuticals reflects a mixed but engaged view, with several firms adjusting price targets after EMANATE and other trial updates, as well as ongoing focus on Imcivree and hypothalamic obesity.RYTM: Hypothalamic Obesity Launch And Upcoming Data Readouts Will Drive Next Upside Phase
Analysts trimmed their blended price target for Rhythm Pharmaceuticals by a few dollars, reflecting slightly more conservative long-term revenue and margin assumptions, even as they continue to highlight the potential of IMCIVREE and the hypothalamic obesity opportunity. Analyst Commentary Recent Street research around Rhythm Pharmaceuticals shows a mix of enthusiasm about the IMCIVREE franchise and the hypothalamic obesity opportunity, along with some recalibration of long-term expectations that feeds into updated price targets.
Rare Obesity Leadership: Can Setmelanotide Scale Beyond the Clinic?
Rhythm Pharmaceuticals enters late February 2026 as the leader in "rare disease obesity," a niche that has remained remarkably insulated from the broader GLP-1 price wars. The company’s core asset, Setmelanotide , has seen rapid uptake in patients with Bardet-Biedl syndrome (BBS) and POMC deficiency, where traditional weight-loss drugs often fail.RYTM: Stable Franchise Trends Will Support Next Phase Of Upside
Analysts have lifted their price target on Rhythm Pharmaceuticals to $145 from $140, citing slightly stronger than expected preannounced Q4 Imcivree revenue of about $57M and what they see as stable growth trends for the existing franchise. Analyst Commentary Recent commentary centers on how the preannounced Q4 Imcivree revenue of about US$57M feeds into expectations for Rhythm Pharmaceuticals' execution and valuation.RYTM: March Review Decision Will Drive Next Phase Of Upside
Analysts lifted their price target on Rhythm Pharmaceuticals to US$145 from US$140, citing Q4 Imcivree revenues of about US$57 million coming in slightly ahead of expectations and their view that growth in the existing franchise remains stable. Analyst Commentary Recent commentary around Rhythm Pharmaceuticals focuses on how the latest Imcivree revenue update might influence expectations for growth, execution, and valuation.RYTM: March Hypothalamic Obesity Decision Will Drive Next Phase Of Upside
Narrative Update Overview Analysts have inched their fair value estimate for Rhythm Pharmaceuticals higher to about $140 from $139, reflecting slightly higher Street price targets and expectations for steady Imcivree demand after a Q4 revenue preannouncement of roughly $57 million. The update also takes into account more cautious views on how much near term upside is left around upcoming label and trial milestones.RYTM: March Obesity Decision And Prader Willi Data Will Shape Upside
Analysts have nudged their fair value estimate for Rhythm Pharmaceuticals higher to about US$139 per share from roughly US$138, reflecting recent price target increases from several firms, along with views that upcoming label expansion and clinical readouts are already largely reflected in the current share price. Analyst Commentary Recent Street research on Rhythm Pharmaceuticals shows a mix of enthusiasm around the commercial trajectory and upcoming label events, alongside some caution on how much of that story is already reflected in the share price.RYTM: March FDA Obesity Decision Will Drive Next Phase Of Upside
Analysts have modestly lifted their fair value estimate for Rhythm Pharmaceuticals to approximately $138 from about $127, reflecting slightly higher long term revenue growth expectations and confidence in upcoming hypothalamic obesity label expansion, despite a recent downgrade on valuation concerns. Analyst Commentary Bullish analysts highlight that Rhythm's strong clinical execution in hypothalamic obesity and Bardet Biedl syndrome, along with robust year to date share performance, support a higher long term revenue trajectory and justify incremental price target increases.Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster
Dec 11RYTM: March FDA Obesity Decision Will Drive Next Phase Of Share Upside
Analysts have edged their average price target for Rhythm Pharmaceuticals slightly higher to about $127 from roughly $126, reflecting confidence that strong Imcivree and bivamelagon data, along with anticipated hypothalamic obesity label expansion, can support continued growth. However, recent gains and a limited near term catalyst slate are tempering enthusiasm.RYTM: December FDA Decision Will Drive Next Phase Of Share Upside
Rhythm Pharmaceuticals' analyst price target increased from $121.43 to $126.31, as analysts cite ongoing clinical progress and upcoming regulatory milestones that support further upside for the company’s shares. Analyst Commentary Analysts have recently weighed in on Rhythm Pharmaceuticals, offering both optimistic and cautionary perspectives based on the company's performance, upcoming catalysts, and valuation.The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Nov 07
RYTM: Upcoming FDA Decision Will Drive Next Phase of Upside Momentum
Analysts have raised their price target for Rhythm Pharmaceuticals from $117.57 to $121.43 per share, citing improved profit margin projections and increased optimism about upcoming label expansions for setmelanotide. Analyst Commentary Recent updates from Street research provide a balanced view on Rhythm Pharmaceuticals, with both bullish and bearish perspectives influencing the company's outlook and valuation.Analysts Boost Rhythm Pharmaceuticals Outlook Amid Setmelanotide Progress and Revised Valuation Metrics
The analyst price target for Rhythm Pharmaceuticals was revised upward by $7 to reflect increased optimism from analysts about the company's potential label expansion and expected regulatory progress for setmelanotide in hypothalamic obesity. Analyst Commentary Recent updates from Street research indicate a positive reassessment of Rhythm Pharmaceuticals' prospects, particularly surrounding potential regulatory approval and expanding commercial opportunities for setmelanotide in hypothalamic obesity.Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines
Rhythm Pharmaceuticals' analyst price target has increased from $114.86 to $118.36, as analysts cite encouraging clinical data and optimism about setmelanotide's approval prospects in hypothalamic obesity. These factors are driving the revised valuation.Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines
The consensus price target for Rhythm Pharmaceuticals was raised to $114.86 as bullish analyst sentiment strengthened on strong Phase 2 obesity trial results, robust Imcivree sales, and optimistic expectations for regulatory milestones and long-term franchise durability. Analyst Commentary Bullish analysts highlight strong Phase 2 trial results for bivamelagon in hypothalamic obesity, demonstrating significant placebo-adjusted BMI reduction at multiple doses and exceeding expectations for efficacy over 14 weeks.Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines
A lower future P/E indicates improved earnings expectations, while a higher discount rate suggests increased perceived risk, yet analysts have still raised Rhythm Pharmaceuticals’ fair value to $110.71 per share. What's in the News Rhythm Pharmaceuticals presented new clinical data on bivamelagon (oral MC4R agonist) and setmelanotide (lead asset) in patients with acquired hypothalamic obesity at ENDO 2025; setmelanotide remains FDA approved for syndromic monogenic obesity due to defined genetic deficiencies.Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%
Jul 10Rhythm Pharmaceuticals (NASDAQ:RYTM) Has Debt But No Earnings; Should You Worry?
Jun 25Label Expansion And Global Healthcare Will Widen Future Market Opportunities
Label expansion and global commercialization of IMCIVREE are set to drive substantial revenue growth and broaden market reach.Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up
May 04Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
Apr 08Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven
Feb 25Rhythm Pharmaceuticals: A Key Year Ahead
Dec 06Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Sep 22Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)
Aug 29Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals: Action Too Specific
Feb 23Stabilitet och tillväxt i betalningar
Hämta utdelningsdata
Stabil utdelning: Otillräcklig data för att avgöra om RYTM s utdelningar per aktie har varit stabila tidigare.
Växande utdelning: Otillräcklig data för att avgöra om RYTM s utdelningsbetalningar har ökat.
Utdelningsavkastning jämfört med marknaden
| Rhythm Pharmaceuticals Utdelningsavkastning jämfört med marknaden |
|---|
| Segment | Utdelningsavkastning |
|---|---|
| Företag (RYTM) | n/a |
| Marknadens lägsta 25% (US) | 1.4% |
| Marknad Topp 25% (US) | 4.2% |
| Genomsnitt för branschen (Biotechs) | 2.6% |
| Prognosanalytiker (RYTM) (upp till 3 år) | 0% |
Anmärkningsvärd utdelning: Det går inte att utvärdera RYTM s utdelningsavkastning mot de lägsta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.
Hög utdelning: Det går inte att utvärdera RYTM s utdelningsavkastning mot de översta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.
Vinstutdelning till aktieägarna
Resultattäckning: Otillräcklig data för att beräkna RYTM s utbetalningskvot för att avgöra om dess utdelningar täcks av intäkter.
Kontantutbetalning till aktieägarna
Kassaflödestäckning: Det går inte att beräkna hållbarheten för utdelningar eftersom RYTM inte har rapporterat några utbetalningar.
Upptäck bolag med stark utdelning
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/30 08:19 |
| Aktiekurs vid dagens slut | 2026/04/29 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Rhythm Pharmaceuticals, Inc. bevakas av 27 analytiker. 16 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |
| Samantha Lynn Semenkow | Citigroup Inc |